HDAC3 Cancer Research Results

HDAC3, Histone Deacetylase 3: Click to Expand ⟱

Source:

Type:

HDAC3 is an enzyme belonging to the class I histone deacetylases and plays a key role in transcriptional regulation by removing acetyl groups from histone tails.
This deacetylase activity leads to chromatin condensation and generally results in transcriptional repression.
HDAC3 is involved in multiple cellular processes, including cell cycle regulation, apoptosis, and differentiation.

HDAC3 is frequently found to be overexpressed in several cancer types, including breast, colorectal, liver, lung, and hematological malignancies.
Elevated HDAC3 levels have been associated with the repression of tumor suppressor genes and deregulation of proliferative pathways.

Pca, Prostate Cancer: Click to Expand ⟱

Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.

Scientific Papers found: Click to Expand⟱

1151-

Api,

Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study

in-vitro,

Pca,

PC3

20–40μM

in-vitro,

Pca,

22Rv1

in-vivo,

NA,

oral intake of apigenin at doses of 20 and 50μg/mouse/day

mouse

TumCCA↑, Apoptosis↑, HDAC↓, P21↑, BAX↑, TumCG↓, Bcl-2↓, Bax:Bcl2↑, HDAC1↓, HDAC3↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Cell Death ⓘ

Apoptosis↑, 1, BAX↑, 1, Bax:Bcl2↑, 1, Bcl-2↓, 1,

Cell Cycle & Senescence ⓘ

P21↑, 1, TumCCA↑, 1,

Proliferation, Differentiation & Cell State ⓘ

HDAC↓, 1, HDAC1↓, 1, HDAC3↓, 1, TumCG↓, 1,
Total Targets: 10

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: HDAC3, Histone Deacetylase 3

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells